Hepion Pharmaceuticals ( (HEPA) ) has released a notification of late filing.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Hepion Pharmaceuticals, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending March 31, 2025. The primary reason for the delay is the ongoing process of compiling necessary information, which could not be completed without unreasonable effort and expense. The company anticipates filing the report within a 5-day extension period. Financially, significant changes are expected, with notable decreases in research and development expenses due to reduced clinical trial costs and headcount. General and administrative expenses also saw a reduction, primarily due to decreased employee stock compensation and salaries. Hepion Pharmaceuticals is committed to maintaining compliance, as evidenced by the signature of Interim CEO John Brancaccio on the notification.
More about Hepion Pharmaceuticals
Average Trading Volume: 4,889,603
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.48M
For a thorough assessment of HEPA stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue